S'abonner

Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome - 27/09/17

Doi : 10.1016/j.ahj.2017.01.016 
Connie N. Hess, MD, MHS a, Robert M. Clare, MS b, Megan L. Neely, PhD b, Pierluigi Tricoci, MD b, c, Kenneth W. Mahaffey, MD d, Stefan K. James, MD, PhD e, f, John H. Alexander, MD, MHS b, c, Claes Held, MD e, f, Renato D. Lopes, MD, PhD b, c, Keith A.A. Fox, MB, ChB g, Harvey D. White, MB, ChB, DSc h, Lars Wallentin, MD, PhD e, f, Paul W. Armstrong, MD i, Robert A. Harrington, MD d, Erik Magnus Ohman, MD b, c, Matthew T. Roe, MD, MHS b, c,
a Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 
b Duke Clinical Research Institute, Durham, NC 
c Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC 
d Department of Medicine, Stanford University, Stanford, CA 
e Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden 
f Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden 
g British Heart Foundation Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom 
h Auckland City Hospital, Green Lane Cardiovascular Service, Auckland, New Zealand 
i Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada 

Reprint requests: Matthew T. Roe, MD, MHS, Duke Clinical Research Institute, 2400 Pratt St, Rm 0311 Terrace Level, Durham, NC 27705.Duke Clinical Research Institute2400 Pratt St, Rm 0311 Terrace LevelDurhamNC27705

Abstract

Objective

Acute coronary syndrome (ACS) trials typically use a composite primary outcome (myocardial infarction [MI], stroke, or cardiovascular death), but differential patient characteristics, timing, and consequences associated with individual component end points as first events have not been well studied. We compared patient characteristics and prognostic significance associated with first cardiovascular events in the post-ACS setting for initially stabilized patients.

Methods

We combined patient-level data from 4 trials of post-ACS antithrombotic therapies (PLATO, APPRAISE-2, TRACER, and TRILOGY ACS) to characterize the timing of and characteristics associated with first cardiovascular events (MI, stroke, or cardiovascular death). Landmark analysis at 7 days after index ACS presentation was used to focus on spontaneous, postdischarge events that were not confounded by in-hospital procedural complications. Using a competing risk framework, we tested for differential associations between prespecified covariates and the occurrence of nonfatal stroke vs MI as the first event, and we examined subsequent events after the first nonfatal event.

Results

Among 46,694 patients with a median follow-up of 358 (25th, 75th percentiles 262, 486) days, a first ischemic event occurred in 4,307 patients (9.2%) as follows: MI in 5.8% (n = 2,690), stroke in 1.0% (n = 477), and cardiovascular death in 2.4% (n = 1,140). Older age, prior stroke/transient ischemic attack, prior atrial fibrillation, and higher diastolic blood pressure were associated with a significantly greater risk of stroke vs MI, whereas prior percutaneous coronary intervention was associated with a greater risk of MI vs stroke. Second events occurred in 32% of those with a first nonfatal stroke at a median of 13 (3, 59) days after the first event and in 32% of those with a first nonfatal MI at a median of 35 (5, 137) days after the first event. The most common second event was a recurrent MI among those with MI as the first event and cardiovascular death among those with stroke as the first event.

Conclusions

Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1 year. Although the profile and prognostic implications of stroke vs MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.

Le texte complet de cet article est disponible en PDF.

Plan


 Vladimir Dzavik, MD served as guest editor for this article.
 Trial registration: ClinicalTrials.gov: PLATO, NCT00391872; APPRAISE-2, NCT00831441; TRACER, NCT00527943; TRILOGY ACS, NCT00699998.


© 2017  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 187

P. 194-203 - mai 2017 Retour au numéro
Article précédent Article précédent
  • Percutaneous revascularization in patients treated with thoracic radiation for cancer
  • Erin A. Fender, Jackson J. Liang, Terence T. Sio, John M. Stulak, Ryan J. Lennon, Joshua P. Slusser, Jonathan B. Ashman, Robert C. Miller, Joerg Herrmann, Abhiram Prasad, Gurpreet S. Sandhu
| Article suivant Article suivant
  • ?-Blocker after acute myocardial infarction
  • Tomoyuki Kawada

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.